Acute Infection
10
1
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Markers of Inflammation and Metabolism in the ER
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform (Perseverance Study)
Development of Antibodies Against Transplant Kidney After Infection
Diagnostic Accuracy of Urine Flow Cytometry in Excluding Bacteruria
Short-Term Use of Antibiotics and Adherence Level
Pediatric ACEs Screening and Resiliency Study
Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)